美國雅培 (ABT) 2008 Q2 法說會逐字稿

Good morning and thank you for standing by.

Welcome to Abbott second quarter 2008 earnings conference call.

All participants will be able to listen-only until the question-and-answer portion of this call.

(OPERATOR INSTRUCTIONS).

Should you become disconnected throughout this conference call, please dial 1-(312)-470-7334 and reference the Abbott call.

This call is being recorded by Abbott.

With the exception of any participants' questions asked during the question-and-answer session, the entire call, including the question-and-answer session, is material copyrighted by Abbott.

It cannot be recorded or rebroadcast without Abbott's expressed written permission.

I would now like to introduce, Mr.

John Thomas, Vice President Investor Relations Sir, you may begin.

Thanks.

Good morning, everyone, and thank you for joining us.

Also on today's call will be Tom Freyman, our Executive Vice President Finance and Chief Financial Officer.

Tom will review the second quarter results and I will discuss the business operating highlights.

Following our comments we will take any questions that you have.

Some statements made today may be forward-looking for purposes of the Private Securities Litigation Reform Act of 1995.

Abbott cautioned that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements.

Economic, competitive, Governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1-A, risk factors to our annual report on Securities and Exchange Commission Form 10-K for the year ended December 31, 2007 and are incorporated by reference.

We undertake no obligation to release publicly any revisions to forward-looking statements as the result of subsequent events or developments.

In today's conference call, as we do in the past, non-GAAP financial measures will be used to help investors understand Abbott's on-going business performance.

These non-GAAP financial measures are reconciled with the comparable GAAP financial measure in our earnings news release and regulatory filings from today, which will be available on our web site at Abbott.com.

So with that I will now turn the call over to Tom.

Tom.

Thanks, John and good morning.

Today we are pleased to announce that Abbott reported a stronger than expected second quarter, with diluted earnings per share of $0.84, which is $0.05 above the midpoint of our previous guidance range of $0.78 to $0.80.

The $0.84 represents EPS growth of nearly 22%.

Approximately half of this out performance can be attributed to higher sales growth across our diverse mix of businesses and geographies and a higher gross margin ratio of 58.4%.

The remainder relates to higher than forecasted other income, reflecting higher on-going payments from Takeda this quarter following the conclusion of the TAP joint venture.

Sales for the quarter were also strong at $7.3 billion an increase of nearly 15% ahead of our previous forecast.

Based on our first-half results, we are very pleased with the performance of the Company as well as the outlook for the remainder of the year and into 2009, when we expect to again deliver double-digit earnings per share growth.

So this morning, before I provide my usual remarks I want to spend a few minutes putting these strong results and first-half accomplishments into context.

What our out performance means in the short-term and over the longer term.

In the near-term, we are raising our full-year on-going earnings per share guidance range to $3.24 to $3.28.

The midpoint of this higher guidance range represents EPS growth of approximately 15%.

At the same time we are raising EPS guidance, we are in a position where we can selectively increase our investment spending this year to support the performance of our most important products, particularly in those businesses where we disproportionately benefit from market growth.

The work we have been doing over the last several years to build and reshape Abbott as an even stronger and more durable growth Company with stainable businesses and a diversified base of earnings, is clearly paying off.

We have positioned the Company to afford the right balance of delivering top tier double-digit earnings growth while investing to sustain growth into 2009 and beyond.

As we assess our performance midyear, we are also very pleased with the Company's consistent level of execution, particularly in the area of clinical and regulatory development, where we have met or exceeded our time lines for regulatory submissions and approvals in virtually every case.

What our management team has said it would do, it has done and what we have said would be approved has been approved.

This year, that list includes eight major new products and indications in the first-half alone, across medical devices, biologics, diagnostics and pharmaceuticals.

Our goal is to provide our investors consistency and durability.

I believe we have achieved that over the last several years, as we have delivered on our commitments in terms of financial performance, strategic actions and regulatory submissions and approvals.

We fully expect this type of performance to continue in the future.

So with that let me turn to provide an overview of our performance in the second quarter, as well as our outlook for the second half of the year.

Sales this quarter increased nearly 15%, including a favorable 5.9% effective exchange rate and some modest sales of Lupron in the US.

Results were strong across each of our global businesses, with pharmaceuticals, diagnostics, vascular and nutritionals all contributing double-digit sales growth with particularly strong performance in international markets.

We also saw good performance from our key growth drivers, including HUMIRA, which was up nearly 50% worldwide and our lipid franchise, which, again, out paced the market.

John will discuss these in more detail in his review of the business operating highlights.

SG&A expense as adjusted increased more than 16%, reflecting investment spending across the businesses in part to support the launches of new products and indications.

R&D increased almost 9%, with continued investment in our broad-based pipeline with early to midstage opportunities across a number of therapeutic areas, including oncology, hematology, hepatitis C, neuroscience and our bioabsorbable stent program.

The adjusted gross margin ratio in the quarter was 58.4%, up 40 basis points from the prior-year and up 160 basis points sequentially from the first quarter reflecting improved business and product mix.

The other income line of the P&L as adjusted was $163 million.

This was related to on-going payments from Takeda following the conclusion of the TAP joint venture.

While in the quarter this was a little more than $60 million above our previous projection, our full-year forecast for these on-going payments remains approximately $300 million.

The tax rate this quarter was 22.3%, slightly higher than our forecasted rate.

The tax rate for the first-half of 2008 was 21%, in line with our previous forecast and our outlook for the full-year rate.

Now let's turn to the outlook for the remainder of 2008.

Today we are raising both our full-year forecast for sales growth and earnings per share.

As I mentioned, we now expect full-year 2008 earnings per share of $3.24 to $3.28, the midpoint of which reflects growth of approximately 15%.

We now expect mid-teens sales growth for the full-year.

We are also forecasting an increase in our level of investment spending as we have identified a number of areas to drive future growth.

As a result, full-year SG&A is expected to increase approximately 15%.

We continue to forecast a gross margin ratio of approximately 58%, for the full-year.

And as I indicated we are forecasting the other income line of the P&L at approximately $300 million for the full-year related to payments from Takeda.

Regarding the tax rate we are confirming our forecast, for a full-year rate of around 21%.

Now let's turn to our outlook for the third quarter.

For the first time we are providing earnings per share guidance of $0.76 to $0.78, the midpoint of which reflects growth of approximately 15%.

Let me walk you through some of the key P&L line items as we forecast them for the third quarter.

We expect sales growth in the mid-teens, R&D up high single-digits, SG&A up mid-teens, other income of approximately $75 million and a tax rate of around 21%.

We forecast the gross margin ratio for the second half of the year at around 58% consistent with our previous forecast.

The ratio is expected to be between 57% and 57.5% in the third quarter and around 59% in the fourth quarter.

This is consistent with the pattern we saw in 2007, with the relatively lower third quarter and relatively higher fourth.

So in summary, as we look at the second quarter, we are very pleased with the performance of our diverse businesses.

We reported stronger than expected sales growth approaching 15%, EPS that beat our original guidance and we raised our earnings per share guidance range for the full-year with the midpoint reflecting growth of 15%.

We are also very pleased to have concluded the TAP joint venture and to receive FDA approval of XIENCE V, which represents a major advance in patient care.

Certainly the favorable trends in the business give us even more confidence as we look toward the future.

Given these factors, we continue to expect double-digit earnings per share growth in 2009 and over the next several years.

With that, let's turn to the business operating highlights.

John.

Thank, Tom.

This morning I will review the quarterly performance of major business segments, pharmaceuticals, nutritionals and medical products, including diabetes care, diagnostics and Abbott Vascular.

So let me start with our medical products businesses, where sales increased 14.7%.

Excuse me.

In our vascular business, global sales were driven by 35% growth internationally as we continue to gain market share with our drug-eluting stent, XIENCE V.

The XIENCE PROMUS platform is now the market leader in Western Europe, surpassing Endeavor, Cypher and TAXUS.

As a result, in the second quarter, our global DES franchise sales, which includes XIENCE, as well as other third-party DES product revenues were $125 million, more than double over the prior-year quarter and up 25% sequentially from the first quarter.

As a reminder, our DES franchise sales include XIENCE, PROMUS and the Medtronic Royalty.

Following the FDA approval two weeks ago today, Abbott's Vascular sales force immediately began launching XIENCE in the US.

We are pleased to bring a superior product offering to market, providing a new alternative to approximately 13 million US patients who have coronary artery disease.

XIENCE is a true next-generation drug-eluting stent with superior performance and durable clinical benefits.

With XIENCE, physicians retain the best-in-class deliverability they've become accustomed to with our market leading MULTI-LINK VISION bare metal stent system, which as you probably know, has more than 60% share in the US.

While we are in the early days of the US XIENCE launch, we are very pleased with our progress to date.

The anecdotal feedback has been extremely positive and demand is quite frankly better than expected.

XIENCE is clearly the preferred product of interventional cardiologists based on clinical data and other distinct performance attributes.

Our goal within the first 30 days of launch is to penetrate the majority of accounts that represent a significant percentage of total US procedure volume.

So although it is still very early, based on the first two weeks of launch, we are right on track with our weekly launch goals if not ahead.

Looking at the DES market broadly, we continue to see steady improvement.

US PCI volumes continue to improve on a sequential quarterly basis and US DES penetration is now in the high 60% range.

We have priced XIENCE to recognize the fair and appropriate value of the product, including its superior clinical data and proven premium attributes.

As a reminder, the US launch of XIENCE is supported by outstanding clinical data.

XIENCE is the first and only drug-eluting stent to demonstrate superiority over the market leading DES in two randomized controlled clinical trials.

XIENCE robust clinical program includes long-term data from the more than 1300 patients enrolled in Spirit First, Spirit II, and Spirit III trials, as well as the continued access and post-approval programs.

Last week we began enrolling our XIENCE V USA post-approval study, which will evaluate patients over the course of five years.

This study will allow physicians to further review the safety and efficacy of XIENCE V in a more complex patient population and continue to gain experience using the product.

Two year data from our larger 1,000 patient US pivotal trial, Spirit III, which we presented at Euro PCR in May, demonstrated the sustained efficacy and safety of XIENCE.

Patients treated with XIENCE experienced better long-term clinical outcomes and lower rates of stent thrombosis than patients treated with TAXUS and we have seen the differences between XIENCE and TAXUS increasing overtime.

At two years in Spirit III, XIENCE demonstrated the following results.

A clinically superior 45% reduction in the risk of major adverse cardiac events or MACE.

A clinically superior 32% reduction in target vessel failure or TDF and a low rate of very late stent thrombosis between one and two years for the ARC definition.

Also in the second quarter, we received approval for XIENCE in South Korea and submitted a marketing authorization license for XIENCE in Japan.

The application for Japan included safety data from the Spirit III clinical trial, including data from a Japanese patient population.

We are forecasting a XIENCE launch in Japan at this time in the second half of 2009.

Also in the quarter we launched StarClose SE, our next-generation vessel closure device, and we did that worldwide.

StarClose SE builds upon the premium clip based design of its predecessor, StarClose, with improved ease of use features.

So as we look ahead to the third quarter, we expect global vascular sales to grow very strong double-digits as we continue to gain share with XIENCE and build on a successful early US launch.

We expect DES franchise sales to nearly double again from the second quarter to approximately $225 million to $250 million in the third quarter.

Let me turn now to our WorldWide Diagnostics business, where sales grew more than 17% in the quarter with continued strong growth in our international business.

We saw 16% growth in our core diagnostics segment this quarter.

This included double-digit growth in the US and internationally.

ARCHITECT sales were up double-digits worldwide as we continue to improve the menu in the United States and introduce new systems.

We recently launched the ARCHITECT i1000, immunoassay instrument for lower volume labs.

Early customer feedback, the i1000 has been positive, as we have already placed more than 200 instruments into the market.

We will showcase the i1000 and other ARCHITECT instruments at the upcoming American Association of Clinical Chemistry or AACC on July 27th through the 31st in Washington DC.

Strong prism sales helped drive US performance in the quarter as well, as customers added the highly anticipated HTLV tests to their instruments.

Emerging markets continue to represent a promising opportunity for future growth in our core diagnostics business as we saw double-digit growth this quarter in both Latin America and China.

Efforts to improve profitability continue to be a significant focus in our core diagnostics business as we evaluate on-going opportunities to reduce overall costs and continue to improve efficiencies.

We are encouraged by the early outcomes of our efforts and anticipate continued margin improvement in that division in the years ahead.

In our Point-of-Care business, sales grew nearly 20% in the quarter.

Growth was driven by strong cardiac cartridge sales and further penetration of our Chem A test, which received acclaim for broader use last year.

In Molecular Diagnostics, sales this quarter increased more than 25%.

Placements for our m2000 real-time PCR system were up worldwide.

In the quarter, we received CE mark for a hepatitis C genotypic typing assay, further expanding our infectious disease menu on the m2000.

We also plan to launch an HPV test for the m2000 internationally by year-end.

In the US, we recently received approval for a Chlamydia, gonorrhea PCR test and have ongoing clinical trails for hepatitis C and B assays.

In the quarter we made an equity investment in Ibis a subsidiary of Isis for the development of a new cutting edge molecular diagnostics technology for the future.

So looking ahead to the third quarter, in our worldwide diagnostics businesses, we anticipate continued double-digit growth.

In Diabetes Care, sales increased more than 9% globally in the quarter driven by strong international sales and increasing adoption of our new no calibration meters FreeStyle Lite and FreeStyle Freedom Lite, which eliminate the manual calibration step required by most glucose meters, improving convenience for people with diabetes.

In the US, sales growth was impacted by the comparison to the prior-year when FreeStyle Lite was first launched.

In the quarter we had strong meter placements representing good prescription growth.

We have seen positive share results on the promotional program we initiated last quarter.

In the third quarter, we expect approximately 10% growth worldwide in Abbott Diabetes Care.

Moving to our Global Nutritional business, sales were up more than 12% in the quarter, driven by 21% growth in international nutritionals, as demand continues to increase for high quality nutritional products, particularly in emerging markets.

We continue to see double-digit growth across both pediatric and adult nutrition products internationally.

US Nutritional sales were up mid-single-digits, driven by strong sales of PediaSure, ZonePerfect, and Glucerna.

Our Similac infant formula brand continues to gain share thanks to the successful introduction of Similac Sensitive, a formula for babies with lactose sensitivities.

In the third quarter, our Nutritional Business, we expect continued strong double-digit growth internationally and continued mid-single-digit growth in the US.

Turning to our Global Pharmaceuticals business, where sales increased nearly 17% in the quarter led by strong reported growth of nearly 27% in international pharmaceuticals.

We expect double-digit sales growth for our Global Pharmaceuticals business to continue in the third and fourth quarters with double-digit growth projected for both the US and international businesses.

US pharmaceutical sales this quarter increased high single-digits despite a difficult comparison to the prior year, reflecting strong, double-digit growth for HUMIRA, Niaspan and Synthroid.

Partially offsetting this performance was the negative impact of generic competition for Omnicef, as well as some modestly lower wholesaler buying this quarter.

In immunology, worldwide HUMIRA sales this quarter were up nearly 50% to $1.1 billion, including more than 70% international growth.

Today, based on the strength of our HUMIRA sales so far this year and our outlook for the remainder of this year we are raising our forecast for full-year global HUMIRA sales to more than $4.3 billion.

Earlier this year we launched HUMIRA for psoriasis and the results have continued to exceed our expectations.

Our US new prescription share in Dermatology has doubled since approval, reaching nearly 30%.

More than 3700 dematologists have written prescriptions for HUMIRA with nearly 1,000 dematologists writing HUMIRA prescriptions for the first time since our psoriasis approval in January.

This significant increase in HUMIRA use by dematologists is promising for the future, because once the profound efficacy is experienced first hand by a physician, we know they're more likely to prescribe HUMIRA again.

Our early success in this market is based on differentiating clinical data.

We have demonstrated that more than 70% of HUMIRA psoriasis patients achieved a 75% reduction in their symptoms, and a remarkable 20% of patients achieved 100% reduction or complete clearance.

Based on outstanding clinical data and the more than a decade of clinical experience with HUMIRA now, we believe we are well positioned for continued success in the dermatology market.

We also continue to see steady growth for HUMIRA in Crohn's disease with total share recently surpassing 40%.

HUMIRA continues to offer the only self administered biologic treatment for Crohn's patients, providing a distinct convenience advantage over the competition.

Other biologic treatments require IV administration or must be reconstituted and administered by a health care professional via multiple injections in the office.

During the quarter, we presented new longer-term Crohn's data at the Digestive Disease Week meeting or DDW, demonstrating HUMIRA's sustainability of remission, with three out of four patients maintaining remission out to two years.

These data are important because Crohn's disease is a life-long, insidious condition with no cure and patients need treatments that demonstrate sustained remission over time.

We also presented new data at the European League Against Rheumatism, or EULAR, meeting demonstrating HUMIRA's proven durability of response across our full suite of rheumatic disease indications.

That's rheumatoid arthritis, psoriatic arthritis and Ankylosing spondylitis, and that was out to seven years.

Additionally, results from analysis of open label studies of HUMIRA in these three distinct indications demonstrate HUMIRA's effectiveness in patients with a previously inadequate response to other anti-TNF therapies.

These data coupled with the five-year radio graphic progression data that's currently in HUMIRA's label, underscore HUMIRA's proven ability to halt disease progression and effectively treat rheumatic disease over the long-term.

HUMIRA continues to represent a major growth driver for the Company, out through the next several years, at least with significant opportunity remaining in both the US and international markets, where penetration rates are currently in the single-digits for biologics.

Today, the global biologics market for all HUMIRA indications is approximately $14 billion.

And that's estimated to exceed $20 billion by 2012.

In our Lipid Management Franchise in the second quarter, our growth continues to out-pace the overall cholesterol market.

Niaspan sales were $194 million in the quarter up nearly 14%.

Currently, more than one million patients are on Niaspan therapy.

We presented additional pivotal Phase III clinical results on our next-generation fenofibric acid molecule,TriLipix, at the National Lipid Association's 2008 Scientific Sessions.

Data from a study of more than 1400 patients with mixed dyslipidemia demonstrated that TriLipix given in combination with AstraZeneca's Crestor met its primary end points and led to greater improvements across all three key lipids compared to mono-therapy.

We also presented data on TriLipix Crestor at the American Diabetes Association annual meeting that demonstrated that TriLipix in combination with Crestor improved key lipids in patients with Type II diabetes.

Patients with Type II diabetes often are at risk for cardiovascular events because of multiple risk factors, including lipid problems and patients with diabetes typically have mixed dyslipidemia at higher rates than nondiabetic patients, a factor that elevates treatment urgency.

Of the more than 21 million American adults with diabetes, more than 14 million have problems affecting one or more of the three key lipid parameters.

As a remainder, these results add to our existing TriLipix data package, including data presented earlier this year demonstrating efficacy and safety of TriLipix in combination with other two leading statins, Lipitor and Zocor.

Our three combination studies, along with the 52-week, long-term open label extension study are part of the largest clinical program to date, designed to evaluate the safety and efficacy of a fibrate in combination with statins.

We submitted TriLipix for FDA approval at the end of last year and remain on track for FDA approval in the fourth quarter of this year.

The next step in our development program is our partnership with AstraZeneca to combine TriLipix and Crestor as a fixed-dose therapy.

The strong data presented at NLA and ADA bode well for our development program that is promising fixed-dose therapy.

This combination product is in Phase III development and we expect to submit for regulatory approval in the second half of next year.

With many unique therapies that address lipid problems beyond LDL alone, Abbott's Lipid franchise is clearly uniquely positioned to address the growing need for comprehensive lipid management now and over the longer term.

So for the full-year, we expect double-digit growth in our lipid franchise.

Moving on to HIV, where Kaletra was up double-digits worldwide in the quarter to $355 million, driven by continued success of the tablet launch in international markets.

And sales of Synthroid this quarter were up double-digits, increasing nearly 12% in the US.

Regarding Depakote during the quarter, we resolved our Depakote ER litigation with a number of companies, providing more certainty around the ER franchise.

As a result, we anticipate generic competition for Depakote ER on January 1st of 2009.

We continue to expect generic competition for Depakote DR upon expiration of pediatric exclusivity later this month, and that's all factored into our forecasts and plans.

Moving on to Lupron, where, this quarter, we integrated the Lupron franchise following the equal split of our TAP joint venture and the conclusion of that agreement.

And we began selling the hormone therapy Lupron as part of our US pharmaceuticals business.

US sales of Lupron this quarter were $81 million reflecting a partial quarter of sales following conclusion of a joint venture.

Lupron sales in the quarter were lower than forecasted due to the commercial transition of the product from our previous TAP joint venture to our Abbott commercial organization.

However, we continue to forecast Lupron sales approaching $400 million in 2008, as we previously indicated.

So in summary, in pharmaceuticals for the third quarter and for the full-year, as I mentioned, we expect double-digit sales growth for both our US and international pharmaceutical businesses.

And finally, as Tom mentioned, our broad-based pipeline continues to be highly productive with eight new major regulatory approvals so far this year in 2008, including four approvals in our pharmaceutical business and four approvals in medical products, with XIENCE V obviously being approved just two weeks ago, today .

We anticipate approval of our next-generation fenofibric acid product, TriLipix, as well as our controlled release branded pain medication Vicodin CR by the end of this year.

In our earlier stage pipeline, we presented data from our novel oncology compounds at ASCO in May.

We also have innovative research programs in neuroscience where a program is underway to address such conditions as ADHD, Alzheimer's Disease, and schizophrenia.

We continue our work in immunology with ABT-874, our IL-12/23 product in late-stage development, as well as other innovative treatments, including oral therapies and other biologic targets.

And in Abbott Vascular, we are leading the way in the development of truly revolutionary new stent technology with our unique and one of a kind bioabsorbable stent program.

So in summary, the Abbott management team we are all very pleased with our overall strong performance from our diverse mix of global businesses and truly best-in-class products, including such products as HUMIRA and XIENCE V that are meeting the critical needs of today's patients.

So with that we will glad to take questions

(OPERATOR INSTRUCTIONS).

Your first question comes from Phil Nalbone.

Your line is open.

Please state your Company.

Thank you very much.

Phil Nalbone with RBC Capital Markets.

Tom, the first question for you relating to the gross margin on an as adjusted basis, we saw a pretty significant sequential jump, 160 basis points, can you remind us what the factors were in the first quarter that led to the weakness and how that whole foreign exchange aspect played out in the second quarter, just kind of walk us through the factors that contributed to that strength in Q2.

Sure, Phil.

In is second quarter a couple of things.

Our business mix was better.

You saw the strong global performance of Pharma, Pharma is a little bit higher percent of sales in the quarter and that contributed nicely.

And in particular, the vascular business, we saw very nice improvement in profitability and gross margin in that business.

That's all geared around XIENCE, both the commercial performance prior to the US launch that is outside the US and also as we prepared for the US launch.

So those are really the factors that caused the improvement sequentially here.

I think if you compared it to the first quarter, it is really even more a story of business and product mix.

After the exchange comments were made in the first quarter we really geared our second quarter forecast to be in line with what we knew at that time.

What you are really seeing now is just everything we have talked about for a long period of time as we have built this Company, and we built these businesses with higher margin products you are seeing some of that come into play and I think that's really what is happening sequentially going from first quarter to second quarter.

Great.

Thank you.

As a follow-on, Tom, St.

Jude confirmed this morning a co-marketing arrangement with Abbott apparently to bundle their CRM products with Abbott's Vascular products.

Can you talk about that arrangement what it might imply for pricing for products such as XIENCE?

I will let John take that question Phil.

Phil, we do have a limited agreement with St.

Jude that basically is in place for those select accounts where there might be interest on the customers part in a CRM and DES contracting solution.

So you might be aware that there was a previous agreement like this in place between St.

Jude and another competitor.

It is directionally similar to that, and really it is expected to be used on a very limited basis, and it has been in place since the launch.

I don't believe it has been used yet.

And based on the past agreement, probably will be used only in a handful of accounts if and when it is needed.

Great.

Thank you very much.

You're welcome.

Our next question comes from Mike Weinstein.

Your line is open and please state your Company.

Thank you.

It's JPMorgan.

Morning.

A couple of questions.

First, John, can you quantify the impact of any wholesaler destocking on the Pharma business, there were a few products, including HUMIRA that were below script trends.

Sure.

We did see some reduced wholesaler buying activity this quarter in particular that affected a couple of our products as you probably noted from the overall growth rates, which were slightly below some estimates on the Street.

That probably impacted US pharmaceutical sales growth approximately a couple of percentage points, and then of course, the other things I talked about had a bigger impact year-over-year comparisons regarding generic, Omnicef, competition and then the Lupron sales, which were additive of course this year to top line growth and estimates that we had.

But as we worked through the closing of the TAP transaction and moving that commercial organization sales force over to underneath Abbott's umbrella we saw a temporary disruption as a result of that.

So our full-year forecast for Lupron we had given at the time of the closing of the transaction of about $400 million is the same for the full-year.

So we will make that up later.

I think the main point on US Pharma is to recognize that we expect strong double-digit growth in the third and the fourth quarter based on HUMIRA, based on all their performance of the other products, the Lipid Franchise, Niaspan, Depakote, which was affected to some degree as well by some of that buying pattern that we saw.

Okay.

Let me touch on a couple of other items.

Your commentary on the drug-eluting stent composite, which you report, your third quarter commentary of $225 million to $250 million.

That was above what were modeled.

We had just over the $200 million.

I would like to get a sense how you are thinking about the cadence of the US launch in terms of market share in and the short-term impact that might have.

Sure.

Well, I guess, it is difficult at this time to put hard data around the launch because it's still to early.

I can tell you though as you can expect, as you might expect, I have been in close contact with the management team at ABD, almost on an hourly basis.

It is going, I would say it is fair to say better than we expected.

The platform acceptance, meaning XIENCE/PROMUS it is better than we expected.

Clearly, the market, the reaction in the market with physicians, intervention cardiologist and hospital administrators were also involved in the purchasing decisions.

It is bifurcated into two segments, those who want XIENCE and PROMUS, and the other products in the market.

So, based on the attributes in the product, the way the launch has gone, although it is early in the first two weeks we feel very confident that we can reach that target range of $225 million to $250 million.

We continue at this point, to estimate market share for XIENCE alone within the first 12 months in the range of 25 to 30%.

But I would say that's based -- and that has been our market share estimate for some time.

That's based on prelaunch estimates.

We will have to evaluate how the launch is going and if it is appropriate at a later time, to raise that estimate, you can be sure that we will do that.

But I think it is fair, and your characterization is fair, as we look at the models that are out there, that estimate of $225 million to $250 million is clearly well above what The Street had expected and we are obviously very pleased with that.

Okay.

Let me ask one final question.

I want to make sure I understand your commentary on the cadence gross margin going forward because it has been a sticking point this quarter was above expectations.

But you are guiding to about 100 basis points or so sequential decline in the third quarter.

I understand some of that should happen because of geography and Depakote IR and and then a big step up, again, in the fourth quarter.

Help me understand the mix cadence and anything else that might going on there that causes gross margins to go down by as much as you are expecting 2Q to 3Q and then the big step up in 4Q?

That's just our global pattern with the Summer months affecting the mix of products and Pharma in particular having a strong fourth quarter and being our highest margin business.

Fourth quarter has always been our highest gross margin quarter.

But, sorry, Tom It is not that severe.

The historical swings from 2Q to 3Q usually aren't 100 basis points down, and then 100 plus basis points up.

I think we saw a decline last year, Mike, and estimating this within a couple of three tick is challenging.

That's what the models show when we look at the mix of businesses.

We will see what happens.

Hopefully it will be better than that but that's our best estimate at this point.

The key thing to remember is we are right on the 58% number that we have forecasting on the first quarter call, for the full-year and the second half.

We're a little better this quarter, which is nice and we expect the year to turn out pretty much the way we forecast on that first quarter call.

Okay.

Great thank you.

Thank you.

Our next question comes from Rick Wise, your line is open.

Please state your Company.

Morning, Tom, morning John.

Hi, Rick.

A couple of things.

First EPS, you took the $3.20, $3.25 to $3.24 to $3.28.

Can you help us understand your thinking, Tom?

The -- a lot of the beat in the quarter as you, as you both called out was the extra TAP income, TAP related income and other.

But the range seems to be you have raised it mostly by that increment.

So you have beaten by our number in consensus by $0.05 but you have raised the bottom in the upper end of the range by $0.04 and $0.03.

Can you help us understand your thinking again?

Thanks.

I think it is pretty much what I said in my remarks.

We've had a great first-half of year and certainly we are passing a good chunk of that on in the guidance for the year.

Again, I would remind you that when you go to the midpoint of the new guidance, we have 15% earnings growth for 2008, and I tell you in this market and in this industry I think that's really stelar EPS growth.

I think this is a good place to be at the end of the second quarter.

I think as we go into the second half of the year we will see how things progress.

The other thing I'd say is it is important to understand a little bit of just the phasing here.

We were a little favorable on the TAP related income on the quarter.

Some of that income materialized earlier than our previous forecast.

So since the full-year is the same number we are a little lower in the second half.

We are not just thinking about 2008 this year.

As I indicated in my remarks, there are a lot of markets here where some degree of investment in the market where we have really the proportionate market share of incremental scripts or whatever the product area is, we really benefit disproportionately.

So we are going to invest in that in the second half.

What that's really going to help is '09 and continue this very strong growth pattern we have seen over the last three, four years of accelerating earnings.

We are just trying to make the right balance here, Rick between giving a very healthy increase in the guidance, getting very strong growth this year in our earnings per share and still building for the future.

I think when you put that all together, we are very bullish about the second-half.

You are going to see sales growth in the second-half, we think stronger than what you saw in the first-half.

And I think when you add it all up, it is a great position to be in as we finish '08 and move into 2009.

Yes, just to be clear, Rick, this is John.

On TAP payments, that was about half of the $0.05 beat and the other half was the fundamental underlying strength of the businesses, which is one of the returns that we increased the earnings range and feel very comfortable about that range in the second half, very comfortable.

That's great.

Very helpful perspective from both of you.

A couple of other follow ups here.

Just to touch on XIENCE quickly, our early physician checks suggest very strong interest in the XIENCE PROMUS family, but a wide range of opinions about XIENCE versus PROMUS mix, mostly driven by price.

At any early read from your perspective, John or Abbott's perspective on your ability to hold your price premium or Boston's aggressiveness, and last, I'll just through it out, Tom, you were giving some longer term perspective and this notion of trying to drive sort of steady acceleration in top and bottom line, which I appreciate.

Can you give us maybe some just bigger picture thoughts on now at that you are in this solid execution phase, talk about cash flow and maybe this quarter the outlook for cash flow.

What you are going to do with it to enhance shareholder value over the next couple of years, give us your larger picture perspective.

Thanks so much.

All right.

Your first question, Rick.

On XIENCE and I will let Tom answer the second part of your question.

I would put it this way, we are very confident, we are winning the majority of accounts against PROMUS.

At the same time, we are not at all surprised that they are selling PROMUS very aggressively.

I think they recognize and I will let them speak for themselves when they have their quarterly call, that the platform is the preferred platform of interventional cardiologist as you recognized and other people have as well.

We're doing the checks in the marketplace.

That's not a surprise to us based on the clinical data, the attributes and other things.

So they recognize that there's a shift in the marketplace and they would rather get something rather than nothing if they have to lose an account.

That being said, I will tell you we feel highly confident in our vascular sales force that we have the best sales force in the industry that has been trained over and over, I can assure you they have been thoroughly prepared for this launch.

They're very incentivize to sale aggressively for us.

We have Abbott, a full compliment of inventory and consignment stocking that we can offer customers.

We have the well forced, well-trained sales force, that they will provide in-servicing training, support to physicians, let's not forget we are the original manufacturer.

So we obviously know this product inside and out.

I think for certain physicians and in fact probably most of them it is important to establish a relationship with a sales force and understand what's in the product pipeline and we have, we think one of the best pipelines in the industry in this particular area with our next-generation drug-coated stent as well as our bioabsorbable stent.

So those things in addition to a very strong offering of some value-added services makes us a very formidable competitor.

We respect Boston Scientific for who they are and what they're capable of doing.

We have a full appreciation for their capabilities but we are going to compete very aggressively as well.

At the same time, I would tell you, as I mentioned in my comments, we expect to get an appropriate and fair value for XIENCE and so far we are seeing that in the marketplace.

There has not been deep discounting in this market.

We expect to get a fair and appropriate value and we are seeing that so far .

At the same time I would tell you we are also, as you know, strong marketers and competitors and we will compete in this

Thank you, John.

You're welcome.

Rick, on the cash flow we had another really good quarter on cash flow, if you look at the year-to-date operating cash flow we are up 18% and it is pretty much the same thing we have been talking about.

We like a balance between strong dividend increases and we have increased that dividend double-digit for a number of years here and had a nice increase this year, and continued share buy back is the other primary area.

We did buy back some additional shares in the quarter and that's really going to be the use of cash flow.

We feel very positive about our ability to drive cash flow at least in line with the earnings growth and we will put it to good use over the next couple of years.

Excellent.

Thank you.

You're welcome.

Our next question comes from Larry Keusch.

Your line is now open.

Please state your Company.

Goldman Sachs.

Good morning, everyone.

John, just starting, I do have a XIENCE question but let me start one other place, which is the comments you made about the US Pharma business and growing double-digit in the third quarter.

What are the drivers that get you to that growth given the fact that you obviously are going to experience generic competition to Depakote IR.

I was a little bit surprised that you guys were still forecasting that solid of growth even with that, with the competition coming.

Yes.

So, well obviously HUMIRA continues to grow robustly and that's the main growth driver of the business right now.

We have been growing that business as we said 50% worldwide, 70% over the last two quarters.

In the US, it has been growing 30% or so.

We expect at least that level of growth as we continue to penetrate, as I mentioned in the strong psoriasis indication and market penetration.

The overall Niaspan, Lipid Franchise, TriCor.

We did have some impact as I mentioned, I think Mike weinstein asked about, was there wholesaler buying activity in the quarter.

There was, that lowered the growth by a couple of percentage points.

We expect that to rectify as we go through back half of the year, that will impact not only TriCor but Kaletra and Depakote as well.

So there's that, the Lupron contribution that I mentioned, $400 million for the full-year.

So there's a lot of positive that are happening in the third and fourth quarter.

And we feel very confident in strong double-digit growth both in the US and internationally as we look out to both of those quarters.

Okay.

And John, on Depakote, would you be willing to just help us understand now that you have got the settlements in place, on the ER version and clarity on the generic competition coming here, how you are thinking about that franchise for the remainder of the year?

Well, we do expect generic competition for DR in early August, and you know, that's factored into all of the forecast that we have given and then of course with the settlement, ER will happen probably in January 1st.

That's factored into our forecast, and again both of those are in the mix of our strong double-digit earnings growth outlook for 2009 and our 15% sales growth outlook for the full-year 2008.

So, we will see some amount of competition there.

We have intentions to protect as much of that as we can and to continue to market that product aggressively as we compete in the marketplace with what is one of the best sales forces.

So that's sort of the general situation.

I can't give you specifics around that, but I would just tell you that we have been very realistic as we have said many times before about our assumption for what happens in that marketplace and that's factored into the growth outlook.

Okay.

Then just lastly, for Tom you certainly have said, certainly over the last six months that you and Miles said that there really isn't any M&A that's on the radar screen.

Again, just given some of your growing cash balances here and the strong cash flow from operations, again if you could just give us a sense of how you are thinking about M&A specifically and then John, on XIENCE are you hearing of pricing aggressively across the nation or is it more geographic on that aggressive pricing from PROMUS?

Larry.

It is Tom.

Nothing new to what we have been saying recently about M&A.

Nothing on the front burner, and we have been active over the years but right now we are in a phase of really executing on the assets we have accumulated and the great products we have in the portfolio.

We are in such a good position to drive top and bottom line now that, we don't need acquisitions to achieve the types of growth rates we are delivering this year, and what we expect to deliver next year and over the next several years.

So anything we would consider would be complimentary to what we have I would say.

But certainly nothing imminent or on the front burner.

Okay.

So, Larry, let me answer your question.

I want to be very clear about this.

I did not indicate they were aggressively discounting or what I said is they're aggressively selling.

I think some other people have suggested there may have been some price discounts.

That's to be expected in certain select accounts.

You are going to have a little bit of that.

But I would tell you so far it is modest.

The value of the franchise in the platform is being upheld as it should be and we are getting fair and appropriate value both on the XIENCE, certainly on the XIENCE side, as well as the PROMUS side.

I don't think it is appropriate for me to comment on their commercial strategy perse, I'll let them do that but we have been very pleased so far and I wouldn't describe the selling price as aggressive, I would describe them aggressively selling the product and the platform, which is what I meant and what we can understand certainly.

Okay.

Great.

Thanks for the clarification.

You're welcome.

Our next question comes from Bruce Nudell.

Your line is open.

Please state your Company.

UBS.

Thanks so much.

I was wondering if you would comment about a couple of questions about the cholesterol franchise.

TriCor was a little below our expectations in the quarter.

What do you foresee the potential growth rate for that drug this year?

Also, when you think about SIMCOR, if you could comment how it is doing so far but in terms of percent of simvastatin scripts that may find their way into SIMCOR formulations.

For frame of reference, AVACOR's 6%, 7% of Lovastatin scripts.

Thanks so much.

Yes, hi, Bruce.

I would say that overall the lipid market growth for the first-half of the year has been modestly lower than expectations for the overall cholesterol market and players.

It has been growing in the low single-digits but the good news is that Abbott's products have been growing faster than the overall market.

We would expect that trend to continue as physicians in the marketplace recognize the importance of adjunctive therapies.

While that is happening in the quarter specifically, as I mentioned before we did see some reduced, wholesaler buying activity around certain products that included TriCor and Niaspan, which would reduce reported growth for the quarter.

But we expect that to improve as the year goes out.

Niaspan, as you saw and we have been talking about has done quite well and I think in the context of the Niaspan/SIMCOR franchise, when we are selling SIMCOR or selling Niaspan we are selling both so our efforts, both of those have helped drive the overall Niaspan, SIMCOR franchise, which is doing quite well.

I think post-ENHANCE, with all of the noise around that, there's a certain level of modest resistance to prescribing combination therapies given what happened with ENHANCE, which was unfortunate.

But we expect that as we get further away from that, the market in general should, should rebound and we will continue to do well.

And we will continue to sell against the attributes of those products, which as you know are strong.

There's no other product on the marketplace like Niaspan that treats HDL as well as it does, and with the issues that the other competitors have had with their attempted development programs, whether it is CTEP or Cordaptive -- those have not happened.

So that obviously gives us a little bit more runway over the next couple of years where we have the exclusive HDL raising product in the marketplace.

But I would tell you as a result of that, we have to do a little bit more heavy lifting on our own and help grow this market.

Some of the investment spending is geared toward that as we help to grow the overall market.

And a follow-up question, pertains to the HUMIRA franchise.

Can you provide an estimate for your patient share in RA and given the upcoming launch of -- or presumptive launch of adalimumab, where do you think your patient share might go over the next several years?

Thanks a lot.

Sure.

RA specifically is -- RA share for HUMIRA is in the 35 to 40% range.

Now, currently we expect that continue to increase.

When we look at competitive products, I think it is safe to say that HUMIRA has the best clinical data in terms of efficacy but also long-term suppression and radio graphic remission.

So our data, our label goes out to five years, physicians have 10 plus years of experience with the product say there's 10 plus years of experience with the product overall.

Physicians are very comfortable with it, clearly they consider it the gold standard in the marketplace, the one to beat.

With respect to [Golimumab] in particular, we are very competitive with them, and very comfortable with the strengths of HUMIRA.

As you probably know, whether it is this product or any others, those that come forth or fifth to market, historically if you look at the overall prescription trends and the overall pharmaceutical market, those that combat late to the game that don't offer clear clinical benefits over the current standard of care, which we don't think that they do based on the data we have seen, particularly the HR scores, they don't typically get more than modest market share.

That would be our expectation for that product.

Thanks so much.

Our next question comes from Larry Biegelsen, your line is open.

Please state your Company.

Larry Biegelsen, Wachovia.

Can you hear me okay.

Yes.

Thanks for taking the question.

Let me ask a question that was asked earlier in a different way.

You beat this quarter, the upper end of the range by about $0.04.

And you raised guidance by $0.03 to $0.04.

But Depakote ER was -- you expect that to go generic, we estimate that that gives you a few cent benefit.

Was there something else that changed, Tom and then I have a follow-up question.

Again I think it is very important to go back to my remarks on the second quarter over performance about half of it was due to earlier than expected income related to the payments from Takeda, associated with the conclusion of the TAP joint venture and the full-year numbers roughly the same.

So that was part of what occurred in the first quarter.

The rest is under lying performance as evidence by the sales growth and the gross margin being higher than we expected.

And that and, that is what is contributing to the raise as well as a little better performance expected in the second half, balanced off by a degree of selective investment spending in some of these areas that are really going to drive market growth for us in the latter part of the year but certainly in 2009.

And if you look at that, again as I said in my remarks we have tried to balance this off in a way that delivers 15% earnings growth for the Company in the year and continues to drive us to very strong earnings growth for years beyond this.

And so again, got to put those two buckets in mind.

I think you see the second half particularly given our revenue forecast of mid-teens growth as being a very strong second half and setting us up very nicely for 2009.

I would just add to that, Larry, as an observation if you compare that 15% EPS bottom line, very favorable to the peers no matter what industry you are looking at.

It is certainly against our purist diversified competitors we are growing at roughly twice their bottom line rate.

I guess the last thing I would say it is midyear and we will see how it goes in the second half.

We like the momentum we are seeing in the business and again, we will see how it is progressing.

That's where we are right now and I think it is a strong statement to raise the guidance the way we did, to deliver the growth rates that we are forecasting and to continue to build for the future.

All right.

(Inaudible) later maybe we will see, not at this time though.

On the pharma side, SIMCOR sales in the quarter and are you still on track to exceed $100 million, and lastly on HUMIRA, the growth in the US was about 29%, the lowest I think US growth rate we have seen.

Is that temporary, and I don't know if you mentioned any wholesaler destocking on that one earlier, John.

Thanks.

The underlying script trends on HUMIRA are a little stronger than that.

We expect that will perform better, stronger.

We are talking about relative performance here of 30% or whether it is going to be 30 or 40%.

But yes we expect to improve in the US.

We look at the business as a whole.

And obviously we did remarkably better than every analysts model that we track on the international side with 70% growth this quarter and last quarter.

So it is the blend of all of those things and that obviously led us to raise our HUMIRA global guidance to more than $4.3 billion for the full-year.

That's pretty good.

So, yes, we expect better outcomes here in the third and fourth quarter.

There was some temporary effects in the quarter that were nonrecurring.

So the underlying strength is very, very strong and we expect good things.

As far as SIMCOR, it is, the sales this quarter were modest because we had the end of the quarter approval and some initial wholesaler buying into that.

So, we saw as expected a leveling off of that in the second quarter and we expect more contribution in the third quarter, third and fourth quarter.

And it will approach $100 million.

I not sure it will get to $100 million.

As I said, some of that is due to the market, which is growing low single-digits overall in the cholesterol market and the effects of ENHANCE, which we think overtime will mediate and then of course when we look at it we talk about Niaspan and SIMCOR together and Niaspan is growing mid teens growth.

We k peck expect that continue.

The combined franchise of Niaspan and SIMCOR should be very close to what we expected earlier in the year.

Thank you.

Yes.

You are welcome.

We have time for one more question, Operator.

Thank you.

We have a question from Sara Michelmore.

Your line is open.

Cowen & Company.

Thank you.

Tom, if I could ask you to talk about the TAP income and particularly can you just talk about the variability that we should expect on the income going forward.

It was obviously higher than you expected this quarter.

How variable is that line item going to be in future quarters and can you give us a sense of what your visibility is on a quarter to quarter basis, how that is going to shake out?

Thanks.

This area, as we indicated before will be a little more volatile than the old TAP joint venture income because there are some events.

As I said on the first quarter call, we are going to forecast those very conservatively so that there are no surprises.

But with the number of roughly $160 million this quarter, the second half is roughly that number as well.

So you can see that there is a degree of variability which, again, part of that was occurred earlier than we thought and when you average it out for the year it is around $300 million.

So we will just have to provide you with that guidance quarter to quarter.

I think the safest thing to do is assume relatively flat and if there's something different coming at any point in time, we will let you know.

Okay.

And can you give us an update on profitability of vascular business both on a cash and non-cash basis?

I know it's been profitable on a cash basis but it has been low profit or close to break even on a non-cash basis.

What should we expect now that you have got the US XIENCE launch underway?

Thanks.

We had a very nice step up in profitability this quarter.

Last year, we were in investment mode this quarter and there actually was a, a loss after amortization as you indicated on a cash basis.

We were making income, but this quarter we turned into an income after amortization, very nice contribution from gross margin from the business.

And we expect the remaining quarters to be profitable this year and obviously accelerating particularly in the fourth quarter when XIENCE really hits stride in the US and volumes are very strong through the manufacturing process.

So, I think we are into profit mode even after amortization for this business and we expect that to be very strong in 2009, obviously that is where the real pay off of getting this US approval and the momentum we seen in Europe, progress we seen.

It is really going to pay off at the bottom line in '09 and it is an important part of our story in '09.

John, I'm sorry if I missed this but an update on the Japanese launch of HUMIRA.

We launched recently as you know, I don't have hard data on that yet.

That process you go through you get approval and then you do pricing and then it has only been a few weeks.

As far as I know it is going well.

That's a market where several hundred million dollar opportunity over the next several years.

We are well positioned there but it is a little early to give specifics.

That's what is happening there.

Before we end Operator, I thought Tom wanted to wrap it up with just a couple of quick comments.

Yes.

Again, I think this is a great quarter for Abbott.

I have been doing this job for eight years and one of the -- this is probably the strongest quarter that I have delivered here.

It was one where we beat the guidance we provide for the quarter, significantly.

We raised our guidance for the year, significantly.

You are looking at a business that is 15% top and bottom line for the year, which I think compared to the industry is truly top tier.

Eight significant approvals in the first-half alone and all of this is driven by the pay off of our diversified mix of products and geography that we built over the last few years that we think is a business that can provide sustainable, durable, double-digit EPS growth in 2009, beyond driven by products like HUMIRA, XIENCE and a number of other products that John talked about today.

Thank you very much for your time today.

Let me just wrap up with the concluding remarks.

The replay will be available after 11:00 a.m.

Central today, on our web site at AbbottInvestor.com and after 11:00 a.m.

Central time via telephone at (203)369-3524 and the confirmation code is 5567501, that's 5567501.

The audio replay will be available until 4:00 on Wednesday, July 23.

We thank you for joining us today.

Please call us if you have any follow ups.

Thank you.

That concludes today's conference thank you for participating.

You may disconnect at this time.